Buprenorphine: Friend or Foe?

*This presentation is no longer eligible for the 1 CE credit*

Medication-assisted treatment (MAT) refers to the practice of integrating counseling and medication to treat substance use disorders. Buprenorphine is one of three medications that are FDA-approved to treat opioid use disorders. The use of buprenorphine beyond the acute withdrawal period is still debated by some addiction treatment providers, despite the strong evidence base that suggests this medication helps many people to sustain recovery.

In this presentation, Harmony’s Medical Director and Chief Clinical Officer will discuss the process and outcomes of the effort to best utilize buprenorphine within the context of comprehensive recovery plans for appropriate individuals.

Annie Peters, Ph.D., LP
Chief Clinical Officer, Harmony Foundation

Dr. Peters is a 2004 alum of Harmony Foundation. In 2008, she completed her PhD in Clinical Psychology from University of Colorado Boulder. She began her addiction treatment career at Hazelden-Betty Ford Foundation as a staff psychologist in 2006 and then as a professor in their Graduate School of Addiction Studies. She joined the Harmony team in 2014 as Chief Clinical Officer.


Dr. Christopher Reveley, MD
Medical Director, Harmony Foundation

Dr. Reveley attended the University of Colorado, Boulder (BA Psychology, 1977) and Dartmouth Medical School (M.D., 1989). After completing residency training at the University of Rochester he worked in the field of anesthesiology until 2012. He completed the Fellowship in Addiction Medicine at the Rushford Center in Middletown, CT, and began as Medical Director at Harmony in 2016. Dr. Reveley has particular interests in refining and focusing medication assisted treatment for those with addiction as well as the evolving, non-traditional, integrated role of medical providers in the residential treatment team.